FDA: Wyeth's DTC for ReFacto has unsubstantiated safety claims

Share this article:
A Wyeth Pharmaceuticals direct-to-consumer brochure for ReFacto antihemophilic factor contains unsubstantiated safety claims, according to an FDA notice of violation letter. The brochure, titled “Bob's World,” contained a “Pathogen Safety” sub-section claiming state-of-the-art manufacturing techniques to optimize pathogen safety.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.